2018
DOI: 10.2147/dmso.s146339
|View full text |Cite
|
Sign up to set email alerts
|

Obesity and nonalcoholic fatty liver disease: current perspectives

Abstract: Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease due to an increase in the prevalence of obesity. The development of NASH leads to an increase in morbidity and mortality. While the first line of treatment is lifestyle modifications, including dietary changes and increased physical activity, there are no approved pharmacological treatment agents for NAFLD and NASH currently. Due to its complex pathophysiology, different pathways are under investigation … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

3
136
0
3

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 203 publications
(153 citation statements)
references
References 57 publications
3
136
0
3
Order By: Relevance
“…Here, we present results from a phase 1 study of the safety, tolerability, PK, and pharmacodynamics (PD) of tropifexor. In addition to lean, healthy volunteers, a cohort of obese volunteers was also included to investigate PK and PD in individuals resembling those with nonalcoholic fatty liver disease/NASH …”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Here, we present results from a phase 1 study of the safety, tolerability, PK, and pharmacodynamics (PD) of tropifexor. In addition to lean, healthy volunteers, a cohort of obese volunteers was also included to investigate PK and PD in individuals resembling those with nonalcoholic fatty liver disease/NASH …”
mentioning
confidence: 99%
“…In addition to lean, healthy volunteers, a cohort of obese volunteers was also included to investigate PK and PD in individuals resembling those with nonalcoholic fatty liver disease/NASH. 21,22…”
mentioning
confidence: 99%
“…Notably, a large number of patients with NAFLD is associated with an increased risk of incident T2DM 3, 4 . But to date, the specifical drug therapy approved for NAFLD have not been found 5, 6 .…”
Section: Introductionmentioning
confidence: 99%
“…In NAFLD, there is no specific target that has been identified that could be exploited to halt the progression of disease, although there are several drugs in clinical trials being developed for this purpose . Several studies have shown improvement or resolution of NAFLD‐induced NASH or cirrhosis in patients after bariatric surgery, however, suggesting that early dietary interventions would be helpful .…”
mentioning
confidence: 99%
“…14 In NAFLD, there is no specific target that has been identified that could be exploited to halt the progression of disease, although there are several drugs in clinical trials being developed for this purpose. 15 Several studies have shown improvement or resolution of NAFLD-induced NASH or cirrhosis in patients after bariatric surgery, however, suggesting that early dietary interventions would be helpful. 16,17 In this study, we assessed the validity of the US-FLI in the average obese BMI population and in a larger cohort of 208 patients with the inclusion of a small group of normal biopsy-proven control patients.…”
mentioning
confidence: 99%